About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Afternoon Driver, I have just spent my Oxs profit on some copper, But still holding Erx, lets hope some positive news soon ( who is CT on the darkside ? )

You can get into trouble for bribing the police in this country, smiler. ;-)

smiler
He sounds like you know who. Have you got any uranium VML looks like the best of the bunch; I bought in last week up 26% already.

Dam !! :)

smiler
Just checked make that 38% it still has a long way to go IMO

I did think it could be driver ! what a Rodney Trotter !!

Just had a look ! :) thanks

good post this morning

mmkv - 19 Feb'07 - 00:59 - 7383 of 7445


http://www.billamag.net/focus-document-text.asp?FocusTextID=53

Not sure if this has been posted on here, but a very interesting report and comparisons..

2 x 2 million at 0.2p just gone through!

A mixed bag today ! a good buying in price !

POT HEAD, WHERE ART THOU BULLSHIT NOW , PROBABLY DOWN THE TOILET ALONG WITH THE CRAP YOU TALK I HOPE
I AM STILL HOLDING 5M

JOINT VENTURE

stop the bullshit and keep holding!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Bought 1 mil today @.19 MM showed this as a sale shares up .03 whats going on?

halifax
Welcome aboard or was it a top up.

let me say this, cause we own 50% of all IPO relating to colon cancer out there, any news on google re colon cancer means the chance its relating to us is 2:1 odds.. bloody good odds if you ask me

http://www.wallstreetreporter.com/interview.php?id=18589&player=wma


if you listen we are intellectual property owners of 50% of all oncology targets which gives significant value. i.e. other pharmas are using our know how!!

and we must not forget this either

Re Gen insiders buy again

Vivian Lewis: "ReGen Therapeutics Plc has received notification from Tigran Kalaydjian that he is beneficially interested in 21,000,000 ordinary shares of the stock representing 3.03% of the current issued share capital.
This came a week after Dr P. Garrod, a non-executive director, that he has acquired 500,000 ordinary shares at 1.15 pence per share. Dr Garrod now holds and is beneficially interested in 66,750,000 ordinary shares representing 9.61% of the current issued share capital. The current price is right where he bought.
A British woman in a vegetative state will be given a sleeping pill which may "wake her up" against her family's wishes, reports the BBC. The 53-year-old, who has not been named, will be given zolpidem which early research has shown can bring people out of a vegetative state. It is being developed by ReGen Therapeutics and is in phase II trials.
After approval by the South African regulatory agency, ReGen Therapeutics Plc ReGen today announced that it has started dosing subjects in a clinical study designed to explore the effects of zolpidem in people who have suffered brain damage.
RGT-London AIM is up sharply, nearly 30%, not because of this development, but because of gossip about a European licensing deal before the end of the year. There is also talk of a takeover bid from an overseas drug company or of a joint venture with Eirx Therapeutics, also of London, traded as ERX. It is a drug discovery company seeking therapies for cancer, and recently announced results of preclinical in vivo animal studies, for its lead compound ERX3722 which was among a lead series of molecules identified from a screen of kinase inhibitors molecules which demonstrated selective killing of breast cancer cells over non-cancerous breast cells."
Editor's Note: Minutewoman.com, a web-based newsletter, provides exclusive monthly tips and analysis on selected international investments. Includes Email alerts to keep subscribers informed of newest briefs.

there is talk of news is out next week re joint venture

coming from you, I believe you !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! NOT

Leading UK scientist in Derry
Baroness Susan Greenfield was the guest of honour at a recent lunch hosted by the NWSTP at the University of Ulster's Magee Campus.

Speaking to an invited audience of senior academics, industrialists and other key stakeholders, Baroness Greenfield, who is regarded as one of the most influential voices in science policy in the UK, discussed her experience of the potential impact of Science and Technology on the regional economy.

In a short address, Baroness Greenfield covered various key and familiar issues including Intellectual Property, Technology Transfer, University Spin-Outs and the mis-match between the mindset of the Investor vs that of the Academic/Scientist.

Baroness Greenfield advocated the collaborative network approach taken by the NWSTP as key in terms of bringing together the various strands of opinion required in order that the impact of Science & Technology is maximized in a region.

She was speaking at the Magee campus during one of a number of engagements in the North West organised by the North West Science and Technology Partnership in collaboration with the University's Step Up programme. During these events, Invest NI were also acknowledged for their contributions through the Western Innovation Network programme managed by NORIBIC.
The Baroness stressed the need for urgent investment into biotechnology if cures are to be found for diseases such as cancer and Alzheimer's.

"Biotechnology is the very area we need to invest in if we are going to cure cancer, if we are going to cure Alzheimer's disease. We do need urgently investment in those areas," she said.

"My own view is that perhaps Government could help by subsidising or giving tax breaks to investors, if you can do it for the film industry, why not do it for the biotech industry.

"It is needed because we are getting increasingly convergent technologies.

"In the news recently, for example we've heard about artificial retina. One can imagine very soon, increasing technologies involving expertise in the biomedical sciences along with physical sciences, information technology and nanotechnology."

Baroness Greenfield also said Government should offer tax breaks or subsidies to investors in the biotechnology field.
Addressing an invited audience of academics and industry leaders, the Baroness stressed the importance of placing science at the centre of the new economy
"These technologies are going to lead to very exciting exploitation, very exciting possibilities for commerce."

Baroness Greenfield is currently a Professor of Pharmacology at Oxford University.

Life Peerage

She was granted a non-political Life Peerage in 2001 and awarded a CBE in the Millennium New Year's Honours List.
She has launched four academic start-up companies and is Director of the Royal Institution of Great Britain.
09 March 2007

From the other side a new patent has been applied for that looks good for ERX if bloody long.